Achromobacter xylosoxidans

The Leeds Method of Management. April, 2008. Achromobacter xylosoxidans [online]. Leeds Regional Adult and Paediatric Cystic Fibrosis Units, St James's University Hospital, Leeds, UK. Available from http://www.cysticfibrosismedicine.com

Introduction

With the widespread use of antibiotics and dramatic improvement in patients survival, newer organisms, such as Stenotrophomonas maltophilia (Denton et al, 1996; Denton et al, 1998; Talmaciu et al, 2000; Krzewinski et al, 2001), Achromobacter xylosoxidans (Dunne & Maisch, 1995; Krzewinski et al, 2001; Tan et al, 2002) and nontuberculous mycobacteria (Tomashefski et al, 1996; Torrens et al, 1998; Olivier et al, 2003) are becoming more widespread. The reasons for their emergence are complex but may relate to the selective pressure exerted by repeated exposure to antibiotic therapy, improved laboratory isolation techniques and enhanced reporting. All may be associated with either simple colonisation or respiratory exacerbations in those persistently colonised with large numbers of these organisms.

Achromobacter xylosoxidans

Achromobacter xylosoxidans, previously named Alcaligenes xylosoxidans is a motile, gram-negative bacillus which is capable of causing infection in patients with cystic fibrosis (CF). The reported prevalence for A. xylosoxidans in CF Centres is lower than that for Stenotrophomonas maltophilia, with rates usually less than 10%, although this appears to be rising (Tan et al, 2002; Lambiase et al, 2006; Ronne Hansen et al, 2006; De Baets et al, 2007). Little is known regarding routes of acquisition, although there are reports of cross-infection between patients (Van Daele et al, 2005). Uncertainty still remains regarding its clinical significance. Tan et al investigated the impact of chronic A. xylosoxidans infection in 13 patients and found no evidence of attributable clinical deterioration two years post-acquisition (Tan et al, 2002). De Baets et al evaluated eight patients with chronic A. xylosoxidans infection and, although they required more courses of antibiotics, the study found no evidence of accelerated decline in respiratory function (De Baets et al, 2007). However, Ronne Hansen et al did find that A. xylosoxidans was associated with declining respiratory function if there was a rapid rise in serum specific precipitating antibodies (Ronne Hansen et al, 2006). A. xylosoxidans is often multi-resistant and clinical data are lacking regarding optimum therapy. In-vitro data suggests that the most active agents may be minocycline, meropenem or imipenem, piperacillin-tazobactam (‘tazocin’) and chloramphenicol (Saiman et al, 2001).

 

Key points

• Uncertainty still remains regarding the clinical significance of Achromobacter xylosoxidans

A. xylosoxidans is often multi-resistant and clinical data are lacking regarding optimum therapy

 

References

De Baets F, Schelstraete P, Van Daele S, et al. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros 2007; 6: 75-78. [PubMed]

Denton M, Todd NJ, Littlewood JM. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1996; 15: 402-405. [PubMed]

Denton M, Todd NJ, Kerr KG, et al. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. J Clin Microbiol 1998; 36: 1953-1958. [PubMed]

Dunne WM Jr, Maisch S. Epidemiological investigation of infections due to Alcaligenes species in children and patients with cystic fibrosis: use of repetitive-element sequence polymerase chain reaction. Clin Infect Dis 1995; 20: 836-841. [PubMed]

Krzewinski JW, Nguyen CD, Foster JM, et al. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis. J Clin Microbiol 2001; 39: 3597-3602. [PubMed]

Lambiase A, Raia V, Del Pezzo M, et al. Microbiology of airway disease in a cohort of patients with cystic fibrosis. BMC Infect Dis 2006; 6: 4-10. [PubMed]

Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 15: 828-834. [PubMed]

Ronne Hansen C, Pressler T, Hoiby N, et al. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients: a retrospective case-control study. J Cyst Fibros 2006; 5: 245-251. [PubMed]

Saiman L, Chen Y, Tabibi S, et al. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol 2001; 39: 3942-3945. [PubMed]

Talmaciu I, Varlotta L, Mortensen J, et al. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol 2000; 30: 10-15. [PubMed]

Tan K, Conway SP, Brownlee KG, et al. Alcaligenes infection in cystic fibrosis. Pediatr Pulmonol 2002; 34: 101-104. [PubMed]

Tomashefski JF Jr, Stern R, Demko CA, et al. Nontuberculous mycobacteria in cystic fibrosis. An autopsy study. Am J Respir Crit Care Med 1996; 154: 523-528. [PubMed]

Torrens JK, Dawkins P, Conway SP, et al. Non-tuberculous mycobacteria in cystic fibrosis. Thorax 1998; 53: 182-185. [PubMed]

Van Daele S, Verhelst R, Claeys G, et al. Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center. J Clin Microbiol 2005; 43: 2998-3002. [PubMed]

Copyright © cysticfibrosismedicine.com